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Introduction
Healthy endothelium inhibits platelet aggregation, platelet adhesion and smooth muscle cell proliferation, and plays a key role in vascular homeostasis with regard to vasodilation and the prevention of atherogenesis. 1 These functions are mediated by the release of different autocrine and paracrine substances such as nitric oxide (NO), which is generated by endothelial NO synthase (eNOS). Experimental data suggest that Rho-associated coiled-coil containing This randomized, double-blind, paralleldesign study compared the short-term effects of rosuvastatin and atorvastatin on serum lipids and markers of inflammation and endothelial function in patients with stable atherosclerosis. Patients received either 10 mg/day rosuvastatin (n = 18) or 20 mg/day atorvastatin (n = 18), orally, for 4 weeks. Serum lipids, high-sensitivity Creactive protein (hsCRP), Rho-associated coiled-coil containing protein kinase (ROCK) activity and flow-mediated dilation (FMD) of the brachial artery were assessed before and after therapy. Both statins produced significant reductions in total cholesterol, low-density lipoprotein cholesterol (LDL-C), triglyceride and hsCRP levels, and significant increases in FMD. Both statins significantly reduced ROCK activity and inhibition was significantly greater with rosuvastatin. There was no correlation between ROCK activity and LDL-C level in either group. There was a significant correlation between ROCK activity and FMD for both statins, but no correlations between FMD and LDL-C or hsCRP levels. Short-term treatment with either rosuvastatin or atorvastatin inhibits ROCK activity independent of cholesterol reduction, and improves endothelium dysfunction in patients with atherosclerosis. B Liu, HM Cao, GY Li et al. Statins, ROCK activity and endothelial function protein kinase (ROCK) decreases the posttranscriptional stabilization of eNOS mRNA. 2 Inhibition of the ROCK pathway decreases vascular smooth muscle cell contraction and proliferation, 3 increases endothelial NO synthesis, 2 and decreases inflammatory cell trafficking and proliferation. 4 There is extensive evidence that statins (3hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) significantly lower total cholesterol and low-density lipoprotein cholesterol (LDL-C) levels, and reduce the risk of coronary heart disease. 5 In addition to their cholesterol-lowering properties, statins have a number of other effects; in particular they improve endothelial dysfunction by preventing the downregulation of ROCK. 6 Endothelium-dependent vascular responses can be measured by assessing flow-mediated dilation of the brachial artery using B-mode ultrasound; this procedure is non-invasive and highly reproducible. 7 Different statins have different pharmacokinetic profiles and chemical structures, 8 which may result in variation in their effects. Rosuvastatin -a relatively new statin -has a powerful lipidlowering action, 9 but little has been reported concerning its effect on endothelial function in patients with atherosclerosis and the possible mechanisms involved in such effects.
The present randomized, double-blind, parallel-design study assessed the short-term effects of rosuvastatin and atorvastatin on serum lipids, high-sensitivity C-reactive protein (hsCRP), ROCK activity and endothelial function in patients with atherosclerosis.
Patients and methods

STUDY POPULATION
Patients with stable atherosclerosis and fasting LDL-C levels > 100 mg/dl without statin therapy were recruited from cardiology clinics held between January 2009 and June 2010 at the following institutes: Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, Jiangsu Province, China; Tongji Hospital, Shanghai, China; and Urumuqi General Hospital of LanZhou Military Command, Urumuqi, China. The presence of atherosclerosis was defined as > 50% stenosis in at least one coronary artery at cardiac catheterization, a history of previous coronary artery bypass graft surgery, previous ischaemic stroke, previous angioplasty, previous myocardial infarction, or documented peripheral arterial disease. Exclusion criteria included any malignancy, acute infection, chronic inflammatory disease, unstable angina or revascularization within 3 months of study enrolment, a history of myositis/myopathy, a serum creatine kinase level greater than the upper limit of normal (> 174 U/l), liver transaminases greater than two times the upper limit of normal (> 400 U/l × 2), and a reluctance to discontinue statin therapy.
Written informed consent was obtained from all patients. The study protocol was approved by the Ethics Committees of Wuxi People's Hospital Affiliated to Nanjing Medical University, Tongji Hospital and Urumuqi General Hospital.
DRUG PROTOCOL
After a 2-week wash-out period, where all patients discontinued statin therapy -a period sufficient to restore endothelial function and lipid profiles to prestatin treatment levels 6 -patients were randomly assigned according to a computer-generated randomization schedule to receive 10 mg rosuvastatin (AstraZeneca, London, UK) or 20 mg atorvastatin (Pfizer, New York, NY, USA), orally, once daily, for 4 weeks. Rosuvastatin was chosen because it is a relatively new drug and has been shown to be highly effective for lowering cholesterol B Liu, HM Cao, GY Li et al. Statins, ROCK activity and endothelial function levels. 10, 11 Atorvastatin was chosen based on its ability to lower LDL-C significantly more than simvastatin, lovastatin, fluvastatin and pravastatin, with similar safety profiles and tolerability. 9,11 A 10 mg/day dose of rosuvastatin is equivalent to a 20 mg/day dose of atorvastatin in terms of its ability to lower LDL-C levels. 12, 13 
CLINICAL ASSESSMENTS
For the measurement of serum lipids, hsCRP and ROCK activity, blood samples for laboratory analyses were collected in heparinized tubes (20 U/ml) in the morning after an overnight fast of approximately 12 h, on at least two occasions both before and after 4 weeks of statin treatment. Blood samples for Western blot analysis were stored at -80°C until analysis. Total cholesterol, high-density lipoprotein cholesterol (HDL-C) and triglyceride levels were measured using standard enzymatic methods. LDL-C was measured and calculated as described previously. 10 The concentration of hsCRP was measured using an immunoturbidimetric assay on a modular system random-access analyser (Dade Behring, Deerfield, IL, USA).
Patient safety evaluation included adverse-event reporting, measurement of vital signs, electrocardiography, physical examination and measurement of various laboratory parameters including serum creatine kinase, hepatic function, creatinine, haematology (routine analysis of red and white blood cells and platelet counts), serum electrolytes and urinalysis.
MEASUREMENT OF ROCK ACTIVITY
To evaluate ROCK activity, Rho kinasedependent phosphorylation of the myosinbinding subunit (MBS) at threonine 853 (phospho-Thr 853 -MBS) was assayed in peripheral blood leucocytes, as described previously. 14 Blood was collected at room temperature in heparinized tubes (20 U/ml) and 10 mM fasudil was added to inhibit ROCK activity and ex vivo formation of phospho-Thr 853 -MBS.
Leucocytes were isolated from the peripheral blood samples (15 ml), suspended and then diluted, as described previously. 13, 15 After the addition of 50% trichloroacetic acid (Sigma-Aldrich, St Louis, MO, USA), 50 mmol/l dichlorodiphenyltrichloroethane (Sigma-Aldrich) and protease inhibitors (Calbiochem, Darmstadt, Germany) to the precipitate protein, Western blot analysis was performed. Briefly, the blots were incubated with rabbit antiphosphospecific Thr 853 -MBS polyclonal antibody or rabbit anti-MBS polyclonal antibody (both from Covance Laboratories, Greenfield, IN, USA), at the manufacturer's recommended dilutions, overnight at 4°C, then washed three times for 10 min each with 1 × Tris-buffered saline-Tween-20 solution (TBST). The blots were then incubated with the appropriate Thermo Scientific DyLight 800-conjugated secondary antibodies (Thermo Fisher Scientific, Rockford, IL, USA), at the manufacturer's recommended dilution, for 1 h at room temperature, and washed a final three times for 10 min each with 1 × TBST. The immunoreactive signal was visualized using an Odyssey fluorescent scanner (LI-COR ® Biosciences, Lincoln, NE, USA). NIH 3T3 cell lysates were used as a positive control. ROCK activity was expressed as the ratio of phospho-Thr 853 -MBS/total MBS normalized to positive controls. 15 
MEASUREMENT OF FLOW-MEDIATED DILATION
Endothelial function was assessed using flow-mediated dilation (FMD) of the brachial artery on two-dimensional ultrasonography before and after 4 weeks of statin treatment. After a 10 -20-min rest in a quiet, dark B Liu, HM Cao, GY Li et al. Statins, ROCK activity and endothelial function room, at a temperature of 22°C, patients were placed in the supine position. Brachial artery diameter was measured in the left arm under baseline conditions and during reactive hyperaemia following 5 min of ischaemic stimulus, induced using a blood pressure cuff placed on the upper arm and inflated to suprasystolic pressures. Digitized images were captured and analysed using Quantity One software, version 22 (Bio-Rad, Hercules, CA, USA). Patients were asked to refrain from taking vasoactive medications on the days on which FMD was performed.
STATISTICAL ANALYSES
All statistical analyses were performed using the SPSS ® statistical package, version 13.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Data are presented as mean ± SE. The baseline characteristics of the two groups were compared using an unpaired Student's t-test or Wilcoxon signed-rank test for continuous variables and the χ 2 -test for categorical variables. Serum lipids, hsCRP, ROCK activity and FMD before and after 4 weeks of statin treatment were compared using a paired Student's t-test for normally distributed variables and the Wilcoxon signed-rank test for non-parametric variables. Pearson's or Spearman's correlation coefficients were used to analyse correlations for parametric and non-parametric variables, respectively. Comparisons between the two groups were performed using an independent t-test or the Wilcoxon rank-sum test. A two-sided P-value < 0.05 was considered to be statistically significant.
Results
A total of 36 patients with stable atherosclerosis were recruited to the study; of these, 18 were randomly assigned to receive rosuvastatin and 18 to receive atorvastatin. Baseline patient characteristics are given in Table 1 . There were no significant differences in age, gender, body mass index, history or medication use between the two groups.
Patients in the rosuvastatin and atorvastatin groups had similar lipid profiles at baseline (Table 2) . Treatment with either rosuvastatin or atorvastatin resulted in equivalent significant reductions in total cholesterol, LDL-C and triglycerides after 4 weeks of therapy (P < 0.05 versus baseline; differences between the two drugs were not statistically significant; Table 2 ). Treatment with rosuvastatin, but not atorvastatin, increased HDL-C levels, but this increase was not statistically significant.
Baseline hsCRP levels did not differ between the two treatment groups ( Table 3) . Treatment with rosuvastatin or atorvastatin for 4 weeks was associated with equivalent significant decreases in hsCRP (P < 0.05 versus baseline; differences between the two drugs were not statistically significant; Table 3 ).
Patients in the two groups had similar ROCK activity at baseline (Table 3) . ROCK activity decreased significantly compared with baseline in patients treated for 4 weeks with rosuvastatin (P < 0.01) and atorvastatin (P < 0.05; Table 3 ). Both statins effectively decreased ROCK activity, but the reduction was significantly greater with rosuvastatin than with atorvastatin (P < 0.05; Fig. 1 ).
Baseline FMD did not differ between the two treatment groups (Table 3) . FMD values increased significantly compared with baseline in patients treated for 4 weeks with rosuvastatin (P < 0.01) and atorvastatin (P < 0.05; Table 3 ). There was no significant difference between the rosuvastatin and atorvastatin-treated groups.
There was no significant correlation between the reduction in ROCK activity and the LDL-C level following rosuvastatin or atorvastatin treatment. There was a significant positive correlation between the B Liu, HM Cao, GY Li et al.
Statins, ROCK activity and endothelial function
changes in ROCK activity and FMD for both rosuvastatin (r = 0.67, P < 0.01) and atorvastatin (r = 0.58, P < 0.05). There was also a modest but non-significant correlation between the reduction in ROCK activity and hsCRP in the rosuvastatin group; no correlation was found between ROCK activity and hsCRP in the atorvastatin group. No correlations were found between changes in FMD and changes in LDL-C or hsCRP.
No serious adverse events were reported during the study. Vital signs and physical 
TABLE 1: Baseline (pretreatment) characteristics of patients with stable atherosclerosis included in the present study to assess short-term effects of 10 mg/day rosuvastatin or 20 mg/day atorvastatin on serum lipids, high-sensitivity C-reactive protein Rho-associated coiled-coil containing protein kinase activity and endothelial function
Discussion
Hypercholesterolaemia impairs endothelial function and is an important risk factor for vascular disease. 16 The vascular endothelium acts as an autocrine and paracrine organ, regulating homeostasis of the vascular wall. Atherosclerosis is a slowly progressive inflammatory disease in which endothelial function is impaired. Lipid-lowering therapies have been observed to reduce atherosclerosis and cardiovascular events effectively. 17 It is well known that the primary effect of statins is to inhibit cholesterol synthesis, causing a decrease in intracellular cholesterol content. The reduction in LDL-C levels observed with 10 mg rosuvastatin were similar to those observed with 20 mg atorvastatin in the present study. Achieving target LDL-C levels at lower doses may be an advantage in patients requiring statin therapy, as this will include many high-risk patients due to the high prevalence of type 2 diabetes, hypertension and other cardiovascular risk factors in these people. 18 Both of the statins used in the present study produced beneficial changes in other lipid measures, including total cholesterol and triglycerides. They were well tolerated over the 4-week study period, with no cases of kidney or liver dysfunction.
In addition to lipid reduction, statins have a wide range of beneficial effects including anti-inflammatory effects 19, 20 and improvement of endothelial dysfunction. 21, 22 It has been shown that their antiinflammatory effects can stabilize and even regress atherosclerotic plaque. 23 The plasma level of hsCRP (an inflammatory marker) was significantly reduced by both statins in the present study, which has important implications for the treatment of coronary artery disease. It is likely that the beneficial effects of statins on endothelial function extend beyond their effects on cholesterol reduction; it has been shown that, despite comparable reductions in serum cholesterol levels with both ezetimibe (an intestinal inhibitor of cholesterol absorption) and the statin simvastatin, only statins are able to improve endothelial function. 24 The effects of statins on endothelial dysfunction have also been demonstrated in in vitro studies. 25 Cerivastatin was shown to potentiate NO release and eNOS expression in endothelial cells through inhibition of isoprenoid biosynthesis via a mevalonatesensitive pathway. 26 The protective effect of statins was completely abolished after inhibition of eNOS. 27 Statins have been reported to inhibit the synthesis of the isoprenoid geranylgeranyl pyrophosphate upstream of cholesterol. 28 It has also been demonstrated that members of the Rho guanosine triphosphatase (GTPase) family -Rho, Rac and CDC42 -are posttranslationally modified by the process of geranylgeranylation, leading to translocation of the Rho GTPases to the membrane. 28 Inactive guanosine diphosphate (GDP)-bound Rho is activated by membrane translocation and subsequent exchange of GDP and guanosine triphosphate (GTP) in the presence of guanine nucleotide exchange factor. 29 Thus, Rho may negatively regulate eNOS. By inhibiting isoprenoid formation, statins decrease the membrane translocation and activation of these small GTPases. Endothelium-derived NO is a pivotal mediator of vasodilation and represents a fundamental physiological mechanism for maintenance of the functional and structural integrities of blood vessels. Direct inhibition of Rho improves FMD in the brachial artery of humans with atherosclerosis, with no influence on LDL-C levels. 30 Alterations in endothelial function precede the development of morphological atherosclerotic changes and can also contribute to lesion development and later clinical complications. 31 B Liu, HM Cao, GY Li et al.
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Both statins evaluated in the present study reduced ROCK activity and improved endothelial function in patients with atherosclerosis, which is consistent with previous studies. Rosuvastatin treatment produced a greater percentage change in FHD of the brachial artery. Among those randomized to receive rosuvastatin, there was a modest though non-significant correlation between ROCK inhibition and reduction in hsCRP after 4 weeks of therapy, which accords with the clinical benefit observed in the JUPITER study of patients with elevated hsCRP levels treated with intensive statin therapy. 32 There were some limitations to the present study. Although the findings showed a significant decline in ROCK activity after statin therapy compared with baseline, inclusion of a placebo arm would have made this result more robust. A placebo group was not included due to the ethical implications of withdrawing statin therapy in patients with atherosclerosis. The present study was small and only observed the short-term effects of two statins at a fixed dose, which is a relatively high starting dose in Asian patients (normal doses rosuvastatin 10 mg/day, atorvastatin 20 mg/day in Asian patients). Further studies are needed, in a larger population, to investigate the longterm effects on these biomarkers and assess clinical outcomes of a titrate-to-goal regimen of rosuvastatin and atorvastatin.
In conclusion, the present study showed that short-term treatment with statins inhibited ROCK activity in patients with atherosclerosis, independent of cholesterol reduction. The ROCK signal transduction pathway may be a potential therapeutic target in patients with atherosclerosis. The clinical relevance of Rho/ROCK inhibition by statins, and its relationship to endothelial function, deserves further study.
